SYNALAR- fluocinolone acetonide solution SYNALAR TS- fluocinolone acetonide kit

Synalar TS by

Drug Labeling and Warnings

Synalar TS by is a Prescription medication manufactured, distributed, or labeled by Medimetriks Pharmaceuticals, Inc., Teligent Pharma Inc, Marketing Advertising Promotions, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

SYNALAR® (fluocinolone acetonide) Topical Solution, 0.01% is intended for topical administration. The active component is the corticosteroid fluocinolone acetonide, which has the chemical name pregna-1,4-diene-3,20-dione,6,9-difluoro-11,21- dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-,(6α,11β,16α)-. It has the following chemical structure:

SYNALAR® Solution contains fluocinolone acetonide 0.1 mg/mL in a water-washable base of citric acid and propylene glycol.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

SYNALAR® Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.

CONTRAINDICATIONS

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS—Pediatric Use).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient

Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions, especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests

The following tests may be helpful in evaluating the HPA axis suppression:

•   Urinary free cortisol test
•   ACTH stimulation test

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy Category C

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalmic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalmic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

• Burning: Perioral dermatitis
• Itching: Allergic contact dermatitis
• Irritation: Maceration of the skin
• Dryness: Secondary infection
• Folliculitis: Skin atrophy
• Hypertrichosis: Striae
• Acneiform eruptions: Miliaria

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

DOSAGE AND ADMINISTRATION

SYNALAR® Solution is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

SYNALAR® (fluocinolone acetonide) Topical Solution, 0.01%

•   60 mL Bottle with applicator tip – NDC: 43538-920-60
•   90 mL Bottle with applicator tip – NDC: 43538-920-90

STORAGE

Store at room temperature 15-25°C (59-77°F); avoid freezing and excessive heat above 40°C (104°F). Store in an upright position.

To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda/gov/medwatch.

SPL UNCLASSIFIED SECTION

Manufactured for:
MEDIMETRIKS PHARMACEUTICALS, INC.
383 Route 46 West, Fairfield, NJ 07004-2402 USA
www.medimetriks.com

Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310

IP030-R6
Rev. 6/18

PRINCIPAL DISPLAY PANEL - 90 mL Bottle Carton

NDC 43538-920-90

For Topical Use Only
Not For Ophthalmic Use

90 mL

Rx Only

SYNALAR®
(fluocinolone acetonide)
Topical Solution, 0.01%

MEDIMETRIKS
PHARMACEUTICALS, INC.

PRINCIPAL DISPLAY PANEL - Kit Carton

NDC 43538-921-90

For Topical Use Only
Not For Ophthalmic Use

90 mL

Rx Only

SYNALAR®
(fluocinolone acetonide)
Topical Solution, 0.01%

TS KIT

KIT CONTAINS:

• 1 - SYNALAR®
  (fluocinolone acetonide)
  Topical Solution, 0.01%
  90 mL Bottle
• 1 - Rehyla® Hair & Body Cleanser
  16 oz. (454 g) Bottle

MEDIMETRIKS
PHARMACEUTICALS, INC.

INGREDIENTS AND APPEARANCE

SYNALAR 
fluocinolone acetonide solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 43538-920
Route of Administration	TOPICAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
fluocinolone acetonide (UNII: 0CD5FD6S2M) (fluocinolone acetonide - UNII:0CD5FD6S2M)	fluocinolone acetonide	0.1 mg  in 1 mL

Inactive Ingredients
Ingredient Name	Strength
propylene glycol (UNII: 6DC9Q167V3)
anhydrous citric acid (UNII: XF417D3PSL)

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 43538-920-90	1 in 1 CARTON	08/15/2012
1		90 mL in 1 BOTTLE, WITH APPLICATOR; Type 0: Not a Combination Product
2	NDC: 43538-920-99	1 in 1 CARTON	08/15/2012
2		13 mL in 1 BOTTLE, WITH APPLICATOR; Type 0: Not a Combination Product

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA015296	08/15/2012

SYNALAR TS 
fluocinolone acetonide kit

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 43538-921

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 43538-921-90	1 in 1 CARTON	08/15/2012

Quantity of Parts
Part #	Package Quantity	Total Product Quantity
Part 1	1 BOTTLE, WITH APPLICATOR	90 mL
Part 2	1 BOTTLE, PUMP	454 g

Part 1 of 2

SYNALAR 
fluocinolone acetonide solution

Product Information
Route of Administration	TOPICAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
fluocinolone acetonide (UNII: 0CD5FD6S2M) (fluocinolone acetonide - UNII:0CD5FD6S2M)	fluocinolone acetonide	0.1 mg  in 1 mL

Inactive Ingredients
Ingredient Name	Strength
anhydrous citric acid (UNII: XF417D3PSL)
propylene glycol (UNII: 6DC9Q167V3)

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1		1 in 1 CARTON
1		90 mL in 1 BOTTLE, WITH APPLICATOR; Type 0: Not a Combination Product

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA015296	11/19/2012

Part 2 of 2

REHYLA HAIR AND BODY 
cleansing (cold creams, cleansing lotions, liquids, and pads) cream

Product Information
Route of Administration	TOPICAL

Other Ingredients
Ingredient Kind	Ingredient Name	Quantity
INGR	water (UNII: 059QF0KO0R)
INGR	sodium C14-16 Olefin Sulfonate (UNII: O9W3D3YF5U)
INGR	glyceryl stearate se (UNII: FCZ5MH785I)
INGR	glycerin (UNII: PDC6A3C0OX)
INGR	cocamidopropyl betaine (UNII: 5OCF3O11KX)
INGR	cetyl alcohol (UNII: 936JST6JCN)
INGR	peg-7 glyceryl cocoate (UNII: VNX7251543)
INGR	dimethicone (UNII: 92RU3N3Y1O)
INGR	cocamidopropyl hydroxysultaine (UNII: 62V75NI93W)
INGR	disodium lauryl sulfosuccinate (UNII: P160Q81342)
INGR	caprylyl glycol (UNII: 00YIU5438U)
INGR	cholesterol (UNII: 97C5T2UQ7J)
INGR	decyl glucoside (UNII: Z17H97EA6Y)
INGR	propylene glycol (UNII: 6DC9Q167V3)
INGR	phenoxyethanol (UNII: HIE492ZZ3T)
INGR	edetate disodium (UNII: 7FLD91C86K)
INGR	hexylene glycol (UNII: KEH0A3F75J)
INGR	salicylic acid (UNII: O414PZ4LPZ)
INGR	chamomile (UNII: FGL3685T2X)
INGR	hyaluronate sodium (UNII: YSE9PPT4TH)
INGR	mica (UNII: V8A1AW0880)
INGR	titanium dioxide (UNII: 15FIX9V2JP)
INGR	xanthan gum (UNII: TTV12P4NEE)

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1		454 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Cosmetic		06/01/2012

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA015296	08/15/2012

Labeler - Medimetriks Pharmaceuticals, Inc. (019903816)

Establishment
Name	Address	ID/FEI	Business Operations
Teligent Pharma Inc		011036910	MANUFACTURE(43538-920, 43538-921)

Establishment
Name	Address	ID/FEI	Business Operations
Marketing Advertising Promotions, Inc.		079486545	PACK(43538-921)